Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, ...

Investors may prefer to hunt for strong dividends right now, as opposed to playing in the volatile stock market. While not as ...

Investors looking to cash in on the fast-growing market for weight management medicines will naturally turn to the two ...

Viking Therapeutics' VENTURE-Oral study of VK2735 has completed enrollment, with a readout set for H2'25. Learn why VKTX ...

At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

Obesity medications in development could improve accessibility and affordability, according to a presenter at Obesity ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2025 results , with sales up 9.4% year on year to $8.15 billion. The company expects the full year’s revenue to be around $35 billion, close to ...